References
- Mattson C, Tanz L, Quinn K, Kariisa M, Patel P, Davis N. Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. Morbidity Mortality Weekly Rep. 2021;70:202–07. doi:https://doi.org/10.15585/mmwr.mm7006a4.
- Amiri S, Lutz R, Socías E, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26–30. doi:https://doi.org/10.1016/j.jsat.2018.07.006.
- Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna‐Taglianti F, Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi‐site prospective cohort study. Addiction. 2007;102:1954–59. doi:https://doi.org/10.1111/j.1360-0443.2007.02025.x.
- Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for opiate injection drug users. J Subst Abuse Treat. 2009;37:120–26. doi:https://doi.org/10.1016/j.jsat.2008.11.004.
- Deck D, Wiitala W, McFarland B, Campbell K, Mullooly J, Krupski A, McCarty D. Medicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states. J Addict Dis. 2009;28:89–102. doi:https://doi.org/10.1080/10550880902772373.
- Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff. 2013;32:1462–69. doi:https://doi.org/10.1377/hlthaff.2012.0846.
- Xiao L, Wu Z, Luo W, Wei X. Quality of life of outpatients in methadone maintenance treatment clinics. J Acquired Immune Deficiency Syndromes (1999). 2010;53:S116. doi:https://doi.org/10.1097/QAI.0b013e3181c7dfb5.
- Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020. doi:https://doi.org/10.31478/202004b.
- Samet JH, Botticelli M, Bharel M. Methadone in primary care - one small step for congress, one giant leap for addiction treatment. N Engl J Med. 2018;379:7–8. doi:https://doi.org/10.1056/NEJMp1803982.
- Abraham AJ, Andrews CM, Yingling ME, Shannon J. Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res. 2018;53:389–404. doi:https://doi.org/10.1111/1475-6773.12686.
- Joudrey PJ, Edelman EJ, Wang EA. Drive times to opioid treatment programs in urban and rural counties in 5 US states. Jama. 2019;322:1310–12. doi:https://doi.org/10.1001/jama.2019.12562.
- Amiri S, McDonell MG, Denney JT, Buchwald D, Amram O. Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis. Value Health. 2020; 24(2):188–195.
- Amiri S, Lutz RB, McDonell MG, Roll JM, Amram O. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment. Am J Drug Alcohol Abuse. 2020;46(1):78–87.
- SAMHSA. OTP guidance for patients quarantined at home with the coronavirus. Administration S.A.a.M.H.S., ed.; Substance Abuse and Mental Health Services Administration; 2020.
- SAMHSA. Opioid Treatment Program (OTP) Guidance. Administration S.A.a.M.H.S., ed.; Substance Abuse and Mental Health Services Administration; 2020.
- Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276. doi:https://doi.org/10.1016/j.jsat.2021.108276.
- Trujols J, Larrabeiti A, Sànchez O, Madrid M, De Andrés S, Duran-Sindreu S. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? J Subst Abuse Treat. 2020;119:108154. doi:https://doi.org/10.1016/j.jsat.2020.108154.
- U.S. Census Bureau. American Community Survey. American Fact Finder. 2017.
- Patton EW, Saia K, Stein MD. Integrated substance use and prenatal care delivery in the era of COVID-19. J Subst Abuse Treat. 2021;124:108273. doi:https://doi.org/10.1016/j.jsat.2020.108273.
- Saulle R, Vecchi S, Gowing L. Supervised dosing with a long‐acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017. doi:https://doi.org/10.1002/14651858.CD011983.pub2.
- Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19. J Subst Abuse Treat. 2021;122:108219. doi:https://doi.org/10.1016/j.jsat.2020.108219.
- Tofighi B, McNeely J, Walzer D, Fansiwala K, Demner A, Chaudhury CS, Subudhi I, Schatz D, Reed T, Krawczyk N. A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic. J Addict Med. 2021. doi:https://doi.org/10.1097/ADM.0000000000000809.
- Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. J Rural Health. 2021. doi:https://doi.org/10.1111/jrh.12570.
- Socías ME, Dong H, Wood E, Brar R, Richardson L, Hayashi K, Kerr T, Milloy M. Trajectories of retention in opioid agonist therapy in a Canadian setting. Int J Drug Policy. 2020;77:102696. doi:https://doi.org/10.1016/j.drugpo.2020.102696.
- Czeisler MÉ, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, Ali N, McMillan H, Wiley JF, Weaver MD, et al. Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — united States, June 2020. Available at SSRN 3675022. 2020. p. 1250–57.
- Gezici A, Ozay O How race and gender shape covid-19 unemployment probability. Available at SSRN 3675022. 2020.